Post-Transplant Lymphoproliferative Disorder- Pipeline Insight, 2019

August 2019 | 60 pages | ID: P79C9A55C5DEN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

"Post-Transplant Lymphoproliferative Disorder- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Post-Transplant Lymphoproliferative Disorder pipeline landscape is provided which includes the disease overview and Post-Transplant Lymphoproliferative Disorder treatment guidelines. The assessment part of the report embraces, in depth Post-Transplant Lymphoproliferative Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-Transplant Lymphoproliferative Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Post-Transplant Lymphoproliferative Disorder Understanding

Post-transplant lymphoproliferative disease (PTLD) is a rare, but well-known complication of solid organ transplants and hematopoietic stem cell transplantation. PTLD is related to the Epstein-Barr virus and immunosuppression therapy. People who receive these transplants are treated with drugs that suppress the activity of the immune system. Doctors must suppress the immune system to help the body accept the transplant and avoid rejection. Individuals receive these drugs at the time of the transplant (induction therapy) and must remain on these drugs for the rest of their lives (maintenance therapy). Immunosuppressive therapy leaves patients at a greater risk of developing infections and, in some people, of developing post-transplant lymphoproliferative disease. Early diagnosis and prompt treatment of these disorders are extremely important.

Post-Transplant Lymphoproliferative Disorder Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Post-Transplant Lymphoproliferative Disorder targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Post-Transplant Lymphoproliferative Disorder pipeline report covers 6+ companies. Some of the key players include Atara Biotherapeutics (Tabelecleucel) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Post-Transplant Lymphoproliferative Disorder Analytical Perspective by DelveInsight

• In-depth Post-Transplant Lymphoproliferative Disorder Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

• Post-Transplant Lymphoproliferative Disorder Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

• The Post-Transplant Lymphoproliferative Disorder report provides an overview of therapeutic pipeline activity for Post-Transplant Lymphoproliferative Disorder across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Post-Transplant Lymphoproliferative Disorder therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Post-Transplant Lymphoproliferative Disorder Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Post-Transplant Lymphoproliferative Disorder

Reasons to Buy

• Establish a comprehensive understanding of the current pipeline scenario across Post-Transplant Lymphoproliferative Disorder to formulate effective R&D strategies
• Assess challenges and opportunities that influence Post-Transplant Lymphoproliferative Disorder R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Post-Transplant Lymphoproliferative Disorder in licensing and out licensing strategies by identifying prospective partners with progressing projects for Post-Transplant Lymphoproliferative Disorder to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER

2.1. Post-Transplant Lymphoproliferative Disorder Disease Overview
2.2. Post-Transplant Lymphoproliferative Disorder History
2.3. Post-Transplant Lymphoproliferative Disorder Symptoms
2.4. Post-Transplant Lymphoproliferative Disorder Causes
2.5. Post-Transplant Lymphoproliferative Disorder Pathophysiology
2.6. Post-Transplant Lymphoproliferative Disorder Diagnosis
  2.6.1. Diagnostic Guidelines

3. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Post-Transplant Lymphoproliferative Disorder companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Post-Transplant Lymphoproliferative Disorder Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Post-Transplant Lymphoproliferative Disorder Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER-PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. Tabelecleucel- Atara Biotherapeutics
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
To be continued in the report…………………………

7. RECENT TECHNOLOGIES

8. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER KEY COMPANIES

8.1. OPi
8.2. Cell Medica
8.3. ViGenCell
8.4. Atara Biotherapeutics
8.5. Achillion Pharmaceuticals
8.6. Viracta Therapeutics

9. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER KEY PRODUCTS

9.1. Elsilimomab
9.2. Baltaleucel-T
9.3. VT EBV
9.4. Tabelecleucel
9.5. ACH 126445
9.6. Nanatinostat

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER- UNMET NEEDS

12. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

Table 1. Post-Transplant Lymphoproliferative Disorder Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Post-Transplant Lymphoproliferative Disorder Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Post-Transplant Lymphoproliferative Disorder companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Post-Transplant Lymphoproliferative Disorder Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

Amgen
OPi
Cell Medica
ViGenCell
Atara Biotherapeutics
Achillion Pharmaceuticals
Mabion
Viracta Therapeutics
bluebird bio